Blood Transfusion Diagnostics Global Market Size, Share, By Product Type, By Application, By Technology, By End User, By Regional Forecast 2024-2033 | Grifols S.A., Abbott Laboratories, Immucor Inc., Quotient Limited, Hologic Inc.

The Blood Transfusion Diagnostics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Blood Transfusion Diagnostics Market:
https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report

According to The Business Research Company’s Blood Transfusion Diagnostics Global Market Report 2024, The blood transfusion diagnostics market size has grown rapidly in recent years. It will grow from $3.98 billion in 2023 to $4.42 billion in 2024 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to increasing blood transfusions, emerging pathogens, aging population, increasing demand for rapid blood transfusion diagnostics, rising prevalence of chronic diseases, increased blood demand.

The blood transfusion diagnostics market size is expected to see rapidly grown in the next few years. It will grow to $6.04 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to rising demand for precision medicine, growing investment in blood transfusion infrastructure, growing demand for molecular blood transfusions, emerging infectious diseases, blood safety concerns. Major trends in the forecast period include advancements in diagnostics, point-of-care testing, automation and robotics, nucleic acid testing (nat), digital integration, expanded pathogen panels, advanced testing technologies.

Patients undergoing surgical procedures need a blood transfusion to replace the lost blood during the procedure. Blood transfusion diagnostics are used during the procedures to screen the blood before transferring it to the patient and will otherwise increase the incidence of infectious disease. According to an article published in the US National Library of Medicine, National Institutes of Health, approximately 310 million surgeries are being performed each year. This increase in the number of procedures will thereby drive the need for blood transfusion diagnostics.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=2494&type=smp

The blood transfusion diagnostics market covered in this report is segmented –
1) By Type: Instruments and Kits, Reagents, Other Types
2) By Technology: Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test
3) By Application: Blood Grouping, Disease Screening
4) By End User: Hospitals, Diagnostic Laboratories, Blood Banks, Plasma Fractionation Companies

Companies in the breast cancer monoclonal antibodies market are investing in targeted and combination therapy, which has proven to be more effective and less toxic than the traditional treatment options. Targeted cancer therapies are drugs or substances that block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Combination therapy uses a treatment method in which a patient is given two or more drugs (or other therapeutic agents) for a single disease. For instance, in May 2022, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, introduced PHESGO, a groundbreaking treatment for breast cancer. PHESGO represents the first-ever fixed-dose formulation in oncology, combining two monoclonal antibodies, Perjeta (pertuzumab) and Herceptin (trastuzumab), with hyaluronidase. It is administered via subcutaneous injection in conjunction with intravenous (IV) chemotherapy for the management of both early and metastatic breast cancer.

The blood transfusion diagnostics market report table of contents includes:
1. Executive Summary